Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development; Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways; and Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33. Zura Bio Limited was founded in 2021 and is based in Henderson, Nevada.

Market Cap	$249.04M	P/E Ratio	N/A
52W High	$4.68	52W Low	$0.97
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	71.7%
Overall Score	55	Value Score	60
Quality Score	--	Technical Score	50

EPS Current Est	$-0.74	EPS Next Est	$-0.77
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ZURA	$3.63	-1.09%	415.25K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ZURA	$3.63	-1.1%	415.25K
3
4
5
6

ZURA

ZURA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Zura Bio Limited Data in Excel

Get Zura Bio Limited Data in Excel